Eli Lil­ly’s USA, di­a­betes chief En­rique Con­ter­no is head­ing out af­ter 27 years, and he’s be­ing re­placed by a ...

6 years ago
People

Zealand takes on Takeda's IBD drug with tiny buy­out

6 years ago
Deals

No­var­tis hands off $80M in cash to part­ner up with a top biotech play­er in the fi­bro­sis sec­tor

6 years ago
R&D

Is there a recipe for M&A suc­cess? The best and worst buy­out deals in the past decade of­fer some keys to suc­cess — ...

6 years ago
R&D

So­ri­ot, Schleifer, Per­reault named top glob­al CEOs — but gone are phar­ma's gold­en years

6 years ago
People

Proven­tion Bio's J&J-li­censed Crohn's drug stum­bles in mid-stage study

6 years ago
R&D

David Liu un­veils newest ad­vance­ment in CRISPR tech: Prime edit­ing

6 years ago
R&D

CD47 play­er Tril­li­um chops dis­cov­ery ef­forts and 40% of staff; Brii Bio inks deal to bring an­tibi­otics to Chi­na

6 years ago
News Briefing

Fra­zier Health­care Part­ner­s' der­ma­tol­ogy up­start at­tracts a mar­quee syn­di­cate, $94M+ for 'in-be­tween' top­i­cal drug

6 years ago
Financing

A new com­pa­ny en­ters the Tec­fidera fight, of­fer­ing to kill two birds

6 years ago
R&D

Bris­tol-My­ers makes Op­di­vo pitch for front­line lung can­cer with open la­bel PhI­II study

6 years ago
R&D
FDA+

In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites ...

6 years ago
R&D

Take­da tees up $420M deal for celi­ac an­ti­dote, con­tin­u­ing R&D re­fo­cus

6 years ago
Deals

Where are the in­ter­change­able biosim­i­lars?

6 years ago
FDA+

FDA re­buffs lit­tle As­ser­tio Ther­a­peu­tic­s' long-act­ing ACTH for­mu­la­tion, shares sink

6 years ago
R&D
FDA+

Failed PhI­II fe­vip­iprant tri­als pour more cold wa­ter on No­var­tis' block­buster R&D en­gine — and briefly spread the ...

6 years ago
R&D

The FDA sets a reg­u­la­to­ry speed record, pro­vid­ing a snap OK for Ver­tex's break­through triplet for cys­tic fi­bro­sis

6 years ago
FDA+

That $335M JV Bay­er set up on CRISPR/Cas9? They’re let­ting the biotech part­ner car­ry on

6 years ago
Deals

J&J's block­buster Ste­lara wins US ap­proval for ul­cer­a­tive col­i­tis

6 years ago
R&D
Pharma

Drug com­pa­nies reach $260M set­tle­ment just ahead of opi­oid tri­al; Oys­ter Point set terms for $85M IPO

6 years ago
News Briefing

Sofinno­va-backed Abi­vax touts longer term mid-stage da­ta in ul­cer­a­tive col­i­tis

6 years ago
R&D

GSK of­floads two vac­cines in $1.1B deal as it works to re­vive the pipeline

6 years ago
Deals

Pfiz­er gets some en­cour­ag­ing PhI­II news on a fran­chise sav­ior, but is a dos­ing ad­van­tage worth the $295M up­front?

6 years ago
R&D

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

6 years ago
R&D
Pharma
First page Previous page 887888889890891892893 Next page Last page
A service from the Financial Times